startup
Sofinnova Partners
Paris-based investor closing oversubscribed €82 million fund to build new MedTech startups.
- 机会评分
- 85 / 100
- 累计融资
- €82 million
- 融资阶段
- unknown
- 成立年份
- unknown
- 地区
- France
- 阶段
- unknown
八个维度
Company · Problem · Solution · Target Customer · Business Model · Funding · Competitors · Why NowCompany
Sofinnova Partners is a life sciences investor specializing in MedTech. Their MD Start IV fund aims to create new MedTech companies, building on a strategy that has already launched around a dozen companies since 2008.
Problem
The need for innovative MedTech solutions to address healthcare challenges, coupled with the difficulty of scaling new MedTech startups.
Solution
Sofinnova Partners provides capital and expertise to build and scale MedTech startups, focusing on unmet clinical needs.
Target Customer
Early-stage MedTech startups with innovative solutions targeting unmet clinical needs.
Business Model
Revenue generated through equity investments in portfolio companies, with exits via acquisitions or IPOs.
Funding
Closed an oversubscribed €82 million fund for MedTech investments.
Competitors
该维度暂无可核实信息（unknown）
Why Now
The increasing demand for innovative MedTech solutions and the success of Sofinnova's existing strategy make this a strategic time to scale.
来源与 AI 标注
模型 · prompt 版本 · 生成时间 · 来源链接相关项目与同赛道
按赛道继续看相关项目1 家
| 公司 | 赛道 | 评分 |
|---|---|---|
| Sofinnova PartnersEuropean life sciences venture capital firm | venture capitallife sciencesmedtech | 85 |
同赛道入口按赛道继续看
数据来自公开渠道与 AI 解读，仅供参考，不构成投资建议。信息可能滞后或有误，决策请以公司官网与官方披露为准。